Clinical Trial Update: Usability of an AI for M923 in Subjects With Moderate to Severe RA [Phase 3]

View source ↗

Summary

This Phase 3 trial update discusses the usability of an AI tool for evaluating M923 in adults with moderate-to-severe rheumatoid arthritis, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• M923

Snippet

Sponsor: Momenta Pharmaceuticals, Inc. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2018-05-01